Albert Tripodi, MD
Internal Medicine · Camillus, NYNPI 1871609974
Payments from drug & device makers
Across 162 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$369
- GSK$348
- Pfizer$275
- Amgen$259
- Novo Nordisk$217
- Boehringer Ingelheim$173
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,11699%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $369 |
| GSK | 17 | $348 |
| Pfizer | 20 | $275 |
| Amgen | 18 | $259 |
| Novo Nordisk | 11 | $217 |
| Boehringer Ingelheim | 9 | $173 |
| Novartis | 8 | $171 |
| Merck | 10 | $156 |
| AbbVie | 8 | $154 |
| Exact Sciences | 6 | $142 |
| Johnson & Johnson | 6 | $136 |
| Lilly USA, LLC | 6 | $121 |
| Teva Pharmaceuticals USA, Inc. | 5 | $84 |
| Corcept Therapeutics | 3 | $81 |
| Insulet Corporation | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 4 | $47 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Bayer | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$109
How this compares
$3,135 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $144,007 |
| IngrezzaValbenazine Tosylate | 12 | $101,327 |
| JardianceEmpagliflozin | 100 | $99,596 |
| XareltoRivaroxaban | 95 | $62,584 |
| OzempicSemaglutide | 57 | $62,441 |
| JanuviaSitagliptin Phosphate | 47 | $61,341 |
| TrulicityDulaglutide | 22 | $35,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $30,101 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $22,117 |
| TradjentaLinagliptin | 19 | $17,921 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $11,011 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,586 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $7,904 |
| OxycontinOxycodone Hcl | 14 | $7,721 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $6,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $275 | $144,007165 claims |
| Boehringer IngelheimJardiance, Tradjenta | $173 | $117,517119 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $22 | $101,32712 claims |
| Johnson & JohnsonXarelto | $136 | $62,58495 claims |
| Novo NordiskOzempic | $217 | $62,44157 claims |
| MerckJanuvia | $156 | $61,34147 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $348 | $52,21787 claims |
| Lilly USA, LLCTrulicity | $121 | $35,27822 claims |
| AstraZenecaSymbicort | $369 | $3,53916 claims |
| AbbVieSynthroid | $154 | $2,02519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Camillus
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.